



10 October 2011

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Conference Invitations

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce that Mrs. Angela Scott, Director of Operations - Cell Therapy, has been invited to attend IBC Life Sciences inaugural Cell Therapy Bioprocessing conference entitled 'Applying the Latest Scientific and Technical Innovations to Build the Bridge from Development to Commercialisation'. The conference runs through 17th and 18th October and is being held in Virginia, USA.

In addition, Dr. Paul Harper, Executive Chairman and Mr. Andrew Carver, Business Development Manager have been invited to present on Angel's Cell Therapy services at the Stem Cell Technology conference hosted by Daniel Stewart & Company on 19th October in London. This underlines the important position that Angel is playing in the development of the Cell Therapy market.

Dr. Harper and Mr. Carver will be presenting alongside Cryo-Save, Epistem and ReNeuron.

For further information:

Angel Biotechnology Holdings plc

Gordon Sherriff, Chief Operating Officer
Lorna Peers, Finance Director

+44 (0) 131 445 6077
www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean / Elliot Berg

+44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce

+44 (0) 20 7947 4350

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon

+44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At



present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 32 people, and a site in Cramlington, near Newcastle-upon-Tyne, which is expected to be commissioned by the end of 2011, initially employing up to 10 people.

More information is available at www.angelbio.com.

- Ends -